SCYNEXIS has demonstrated success in advancing innovative therapies through strategic alliances with leading biopharmaceutical organizations. Our partnering approach is focused on creating mutually beneficial relationships that accelerate development, expand global reach, and maximize the value of promising therapies for patients with severe rare diseases, while leveraging the complementary strengths and capabilities of our partners.
In March 2026, SCYNEXIS entered into a definitive agreement with Poxel S.A. (Poxel.PA), a clinical-stage biopharmaceutical company, to acquire PXL-770 (now SCY-770). SCY-770, a novel and highly selective, direct AMP-activated protein kinase (AMPK) activator, is being developed as a disease modifying therapy for ADPKD, a progressive genetic kidney disorder with significant unmet medical need.
In March 2023, SCYNEXIS and GSK (LSE/NYSE: GSK) signed an exclusive license agreement, amended in Dec 2023 and Oct 2025, to commercialize BREXAFEMME® (ibrexafungerp tablets) for vulvovaginal candidiasis (VVC) and recurrent VVC (rVVC) and further develop ibrexafungerp as a potential treatment for life-threatening fungal infections. GSK has the rights to develop ibrexafungerp and commercialize BREXAFEMME in all countries except the greater China region and certain other countries already out-licensed by SCYNEXIS to third parties.
In February 2021, we announced a licensing and strategic partnership agreement for ibrexafungerp with Hansoh Pharma, one of the largest biopharmaceutical companies in Greater China and in Asia, that covers the Greater China region. We received a $10 million upfront payment and are eligible to receive development and commercial milestone payments of up to $112 million, plus low double-digit royalties on net sales.
Ibrexafungerp (formerly SCY-078) was initially discovered at our research facilities and developed as part of a research collaboration with Merck. Subsequently, all worldwide intellectual property, development and commercialization rights were transferred to SCYNEXIS. Following the out-licensing of ibrexafungerp to GSK, clinical development and commercialization responsibilities are now being advanced by GSK under the terms of the collaboration agreement.